Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselve...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Nature Publishing Group
2018
|
| Online Access: | http://hdl.handle.net/1721.1/116537 https://orcid.org/0000-0003-1689-0784 https://orcid.org/0000-0002-4233-0775 https://orcid.org/0000-0002-6702-4192 https://orcid.org/0000-0001-5785-8911 |
| _version_ | 1826210175200002048 |
|---|---|
| author | Sayin, Volkan I. Singh, Simranjit X. LeBoeuf, Sarah E. Karakousi, Triantafyllia R. Martinez, Britney Bronson, Roderick T. Prigge, Justin R. Schmidt, Edward E. Thomas, Craig J. Goparaju, Chandra Davies, Angela Dolgalev, Igor Heguy, Adriana Allaj, Viola Poirier, John T. Moreira, Andre L. Rudin, Charles M. Pass, Harvey I. Papagiannakopoulos, Thales Davidson, Shawn M. Bauer, Matthew R. Ellis, Donald Christian Bhutkar, Arjun Sanchez-Rivera, Francisco Javier Subbaraj, Lakshmipriya Vander Heiden, Matthew G. Jacks, Tyler E. Romero, Rodrigo,Ph. D.Massachusetts Institute of Technology. |
| author2 | Massachusetts Institute of Technology. Department of Biology |
| author_facet | Massachusetts Institute of Technology. Department of Biology Sayin, Volkan I. Singh, Simranjit X. LeBoeuf, Sarah E. Karakousi, Triantafyllia R. Martinez, Britney Bronson, Roderick T. Prigge, Justin R. Schmidt, Edward E. Thomas, Craig J. Goparaju, Chandra Davies, Angela Dolgalev, Igor Heguy, Adriana Allaj, Viola Poirier, John T. Moreira, Andre L. Rudin, Charles M. Pass, Harvey I. Papagiannakopoulos, Thales Davidson, Shawn M. Bauer, Matthew R. Ellis, Donald Christian Bhutkar, Arjun Sanchez-Rivera, Francisco Javier Subbaraj, Lakshmipriya Vander Heiden, Matthew G. Jacks, Tyler E. Romero, Rodrigo,Ph. D.Massachusetts Institute of Technology. |
| author_sort | Sayin, Volkan I. |
| collection | MIT |
| description | Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselves may lead to therapeutic vulnerabilities in tumors. Approximately 20% of KRAS-mutant LUAD tumors carry loss-of-function mutations in the KEAP1 gene encoding Kelch-like ECH-associated protein 1 (refs. 2, 3, 4), a negative regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcriptional regulator of the endogenous antioxidant response. The high frequency of mutations in KEAP1 suggests an important role for the oxidative stress response in lung tumorigenesis. Using a CRISPR-Cas9-based approach in a mouse model of KRAS-driven LUAD, we examined the effects of Keap1 loss in lung cancer progression. We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice. Through a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses, we show that Keap1- or Nrf2-mutant cancers are dependent on increased glutaminolysis, and this property can be therapeutically exploited through the pharmacological inhibition of glutaminase. Finally, we provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition. |
| first_indexed | 2024-09-23T14:45:05Z |
| format | Article |
| id | mit-1721.1/116537 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T14:45:05Z |
| publishDate | 2018 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | mit-1721.1/1165372022-10-01T22:16:34Z Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis Sayin, Volkan I. Singh, Simranjit X. LeBoeuf, Sarah E. Karakousi, Triantafyllia R. Martinez, Britney Bronson, Roderick T. Prigge, Justin R. Schmidt, Edward E. Thomas, Craig J. Goparaju, Chandra Davies, Angela Dolgalev, Igor Heguy, Adriana Allaj, Viola Poirier, John T. Moreira, Andre L. Rudin, Charles M. Pass, Harvey I. Papagiannakopoulos, Thales Davidson, Shawn M. Bauer, Matthew R. Ellis, Donald Christian Bhutkar, Arjun Sanchez-Rivera, Francisco Javier Subbaraj, Lakshmipriya Vander Heiden, Matthew G. Jacks, Tyler E. Romero, Rodrigo,Ph. D.Massachusetts Institute of Technology. Massachusetts Institute of Technology. Department of Biology Koch Institute for Integrative Cancer Research at MIT Romero, Rodrigo Davidson, Shawn M. Bauer, Matthew R. Ellis, Donald Christian Bhutkar, Arjun Sanchez-Rivera, Francisco Javier Subbaraj, Lakshmipriya Vander Heiden, Matthew G. Jacks, Tyler E. Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselves may lead to therapeutic vulnerabilities in tumors. Approximately 20% of KRAS-mutant LUAD tumors carry loss-of-function mutations in the KEAP1 gene encoding Kelch-like ECH-associated protein 1 (refs. 2, 3, 4), a negative regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcriptional regulator of the endogenous antioxidant response. The high frequency of mutations in KEAP1 suggests an important role for the oxidative stress response in lung tumorigenesis. Using a CRISPR-Cas9-based approach in a mouse model of KRAS-driven LUAD, we examined the effects of Keap1 loss in lung cancer progression. We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice. Through a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses, we show that Keap1- or Nrf2-mutant cancers are dependent on increased glutaminolysis, and this property can be therapeutically exploited through the pharmacological inhibition of glutaminase. Finally, we provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition. 2018-06-22T19:12:01Z 2018-06-22T19:12:01Z 2017-10 2017-04 2018-06-22T18:43:43Z Article http://purl.org/eprint/type/JournalArticle 1078-8956 1546-170X http://hdl.handle.net/1721.1/116537 Romero, Rodrigo et al. “Keap1 Loss Promotes Kras-Driven Lung Cancer and Results in Dependence on Glutaminolysis.” Nature Medicine (October 2017): 1362–1368 © 2017 Nature America, Inc., part of Springer Nature https://orcid.org/0000-0003-1689-0784 https://orcid.org/0000-0002-4233-0775 https://orcid.org/0000-0002-6702-4192 https://orcid.org/0000-0001-5785-8911 http://dx.doi.org/10.1038/NM.4407 Nature Medicine Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf Nature Publishing Group PMC |
| spellingShingle | Sayin, Volkan I. Singh, Simranjit X. LeBoeuf, Sarah E. Karakousi, Triantafyllia R. Martinez, Britney Bronson, Roderick T. Prigge, Justin R. Schmidt, Edward E. Thomas, Craig J. Goparaju, Chandra Davies, Angela Dolgalev, Igor Heguy, Adriana Allaj, Viola Poirier, John T. Moreira, Andre L. Rudin, Charles M. Pass, Harvey I. Papagiannakopoulos, Thales Davidson, Shawn M. Bauer, Matthew R. Ellis, Donald Christian Bhutkar, Arjun Sanchez-Rivera, Francisco Javier Subbaraj, Lakshmipriya Vander Heiden, Matthew G. Jacks, Tyler E. Romero, Rodrigo,Ph. D.Massachusetts Institute of Technology. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis |
| title | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis |
| title_full | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis |
| title_fullStr | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis |
| title_full_unstemmed | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis |
| title_short | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis |
| title_sort | keap1 loss promotes kras driven lung cancer and results in dependence on glutaminolysis |
| url | http://hdl.handle.net/1721.1/116537 https://orcid.org/0000-0003-1689-0784 https://orcid.org/0000-0002-4233-0775 https://orcid.org/0000-0002-6702-4192 https://orcid.org/0000-0001-5785-8911 |
| work_keys_str_mv | AT sayinvolkani keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT singhsimranjitx keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT leboeufsarahe keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT karakousitriantafylliar keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT martinezbritney keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT bronsonroderickt keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT priggejustinr keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT schmidtedwarde keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT thomascraigj keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT goparajuchandra keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT daviesangela keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT dolgalevigor keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT heguyadriana keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT allajviola keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT poirierjohnt keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT moreiraandrel keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT rudincharlesm keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT passharveyi keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT papagiannakopoulosthales keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT davidsonshawnm keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT bauermatthewr keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT ellisdonaldchristian keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT bhutkararjun keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT sanchezriverafranciscojavier keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT subbarajlakshmipriya keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT vanderheidenmatthewg keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT jackstylere keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis AT romerorodrigophdmassachusettsinstituteoftechnology keap1losspromoteskrasdrivenlungcancerandresultsindependenceonglutaminolysis |